Premium
Alpha 1 ‐acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125
Author(s) -
Mogensen Ole,
Mogensen Bent,
Jakobsen Anders
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19891101)64:9<1867::aid-cncr2820640919>3.0.co;2-y
Subject(s) - medicine , ovarian cancer , cancer antigen , cancer , antigen , oncology , cancer research , immunology
Serum values of alpha 1 ‐acid glucoprotein (α 1 ‐AG) were measured by a radial immunodiffusion technique before the primary operation of 60 ovarian tumors and before the second‐look laparotomy of 80 ovarian carcinomas. The results were compared with cancer antigen 125 (CA 125) measurements performed in the same samples by a radioimmunoassay or enzymeimmunoassay. The sensitivity and negative predictive value of the α 1 ‐AG measurements were low both before the primary operation (37% and 31%, respectively) and the second‐look operation (10% and 51%, respectively). Inversely, the CA 125 measurements before the primary operation demonstrated a sensitivity and negative predictive value of 93% and 81%, respectively. In the second‐look group the corresponding CA 125 results were 41% and 62%, respectively. The specificity and positive predictive value of α 1 ‐AG before the primary and the second‐look operation were high and almost identical to those of CA 125 (93%–100%). All patients with increased α 1 ‐AG values also had increased CA 125 levels. Alpha 1 ‐AG cannot be distinguished from immunosuppressive acidic protein (IAP) by radial immunodiffusion technique. In conclusion, the α 1 ‐AG analyses did not add new information to the CA 125 measurements. The use of α 1 ‐AG (or IAP) as a tumor marker in ovarian cancer cannot be recommended.